Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 40Lymphoma 7Waldenstrom Macroglobulinemia 3Recurrence 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Amyloidosis 2Smoldering Multiple Myeloma 1Plasmacytoma 1Plasmablastic Lymphoma 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1

Interventions

Dexamethasone 9Calcium Dobesilate 7Bortezomib 5Melphalan 4Cyclophosphamide 3ixazomib 2Thalidomide 2Doxycycline 2dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1birtamimab 1auricularum 1Tacrolimus 1Lenalidomide 1Etoposide 1Doxorubicin 1Cisplatin 1Bendamustine Hydrochloride 1Antilymphocyte Serum 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Amyloidosis × ixazomib × Clear all
NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Mayo Clinic

Phase 1/2 Completed
87 enrolled 13 charts
Plasma cell

Amyloidosis, Multiple Myeloma

NCT02924272 2025-03-12

Ixazomib Rollover Study

Takeda

Phase 2 Completed
32 enrolled 13 charts
LymphoidPlasma cell

Amyloidosis, Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡